Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration
- 989 Downloads
Since glomerular filtration rate (GFR) is responsible for the elimination of a large number of water-soluble drugs, the aim of this study was to develop a semi-physiological function for GFR maturation from neonates to adults.
In the pharmacokinetic analysis (NONMEM VI) based on data of gentamicin, tobramycin and vancomycin collected in 1,760 patients (age 1 day–18 years, bodyweight 415 g–85 kg), a distinction was made between drug-specific and system-specific information. Since the maturational model for clearance is considered to contain system-specific information on the developmental changes in GFR, one GFR maturational function was derived for all three drugs.
Simultaneous analysis of these three drugs showed that maturation of GFR mediated clearance from preterm neonates to adults was best described by a bodyweight-dependent exponent (BDE) function with an exponent varying from 1.4 in neonates to 1.0 in adults (ClGFR = Cldrug*(BW/4 kg)BDE with BDE = 2.23*BW−0.065). Population clearance values (Cldrug) for gentamicin, tobramycin and vancomycin were 0.21, 0.28 and 0.39 L/h for a full term neonate of 4 kg, respectively.
Based on an integrated analysis of gentamicin, tobramycin and vancomycin, a semi-physiological function for GFR mediated clearance was derived that can potentially be used to establish evidence based dosing regimens of renally excreted drugs in children.
KEY WORDSantibiotics developmental changes glomerular filtration pediatric age range
Glomerular filtration rate
Normalized prediction distribution error method
ACKNOWLEDGMENTS AND DISCLOSURES
This study was performed within the framework of Top Institute Pharma project number D2-104. The clinical research of K. Allegaert is supported by the Fund for Scientific Research, Flanders (Belgium) (clinical fellowship 1800214N) and has been supported by an IWT-SBO project (130033). The clinical research of J. van den Anker is supported by NIH grants (R01HD060543, K24DA027992, R01HD048689, U54HD071601) and FP7 grants TINN (223614), TINN2 (260908), NEUROSIS (223060), and GRIP (261060). The authors also would like to thank LAP&P Consultants for their technical support with NONMEM.
- 6.Krekels EHJ, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, et al. From pediatric covariate model to semiphysiological function for maturation: part I–extrapolation of a covariate model from morphine to zidovudine. CPT: Pharmacometrics & Systems Pharmacology. 2012;1:e9. doi: 10.1038/psp.2012.11. Published online 3 October 2012.Google Scholar
- 7.Krekels EHJ, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D, et al. From pediatric covariate model to semiphysiological function for maturation: part II—sensitivity to physiological and physicochemical properties. CPT: Pharmacometrics & Systems Pharmacology. 2012;1:e10. doi: 10.1038/psp.2012.12. Published online 10 October 2012.Google Scholar
- 19.Administration FaD. Guidance for industry - E11 clinical investigation of medicinal products in the pediatric population 2000. Available from http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129477.pdf.
- 23.Farmacotherapeutisch kompas. Referentiewaarden klinische chemie. Available from: http://www.fk.cvz.nl/default.asp?soort=tekst&naam=inl referentiewaarden klinische chemie.
- 26.Montgomery DC, Peck EA. Introduction to linear regression analysis. New York: Wiley; 1982. p. 301–2.Google Scholar
- 38.De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, et al. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res. 2014;31(3):754–67.Google Scholar
- 41.Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol. 2012. doi: 10.1111/j.1365-2125.2012.04406.x.Google Scholar